Cytek Biosciences, Inc. (CTKB)

Cytek Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	201.49	200.45	193.02	164.04	127.95
Revenue Growth (YoY)	0.52%	3.85%	17.67%	28.20%	37.82%
Cost of Revenue	97.03	89.35	83.59	63.06	48.81
Gross Profit	104.46	111.11	109.43	100.97	79.14
Selling, General & Admin	108.38	92.23	93.12	67.92	45.55
Research & Development	36.47	39.4	44.15	34.86	24.44
Total Operating Expenses	144.84	131.63	137.27	102.78	69.99
Operating Income	-40.38	-20.52	-27.85	-1.8	9.16
Interest Income	2.22	5.12	6.41	4.62	0.05
Interest Expense	-	-	-	-	-1.74
Other Non-Operating Income (Expense)	8.33	9.7	5.72	-1.56	-1.53
Total Non-Operating Income (Expense)	10.54	14.82	12.14	3.06	-3.22
Pretax Income	-29.84	-5.7	-15.71	1.26	5.94
Provision for Income Taxes	36.7	0.32	-3.56	-1.22	2.91
Net Income	-66.54	-6.02	-12.15	2.58	6.05
Minority Interest in Earnings	-	-	-	0.09	-3.03
Net Income to Common	-66.54	-6.02	-12.15	2.58	6.05
Net Income Growth	-	-	-	-57.45%	88.25%
Shares Outstanding (Basic)	128	131	135	135	77
Shares Outstanding (Diluted)	128	131	135	139	82
Shares Change (YoY)	-2.19%	-3.45%	-2.37%	69.93%	150.13%
EPS (Basic)	-0.52	-0.05	-0.09	0.02	-
EPS (Diluted)	-0.52	-0.05	-0.09	0.02	-
Free Cash Flow	-8.77	21.85	0.63	-21.98	0.27
Free Cash Flow Growth	-	3352.45%	-	-	-98.05%
Free Cash Flow Per Share	-0.07	0.17	0.00	-0.16	0.00
Gross Margin	51.84%	55.43%	56.69%	61.56%	61.86%
Operating Margin	-20.04%	-10.24%	-14.43%	-1.10%	7.16%
Profit Margin	-33.02%	-3.00%	-6.29%	1.51%	2.37%
FCF Margin	-4.35%	10.90%	0.33%	-13.40%	0.21%
EBITDA	-28.41	-10.03	-18.62	3.86	10.4
EBITDA Margin	-14.10%	-5.01%	-9.64%	2.35%	8.13%
EBIT	-40.38	-20.52	-27.85	-1.8	9.16
EBIT Margin	-20.04%	-10.24%	-14.43%	-1.10%	7.16%
Effective Tax Rate	-122.98%	-5.61%	22.67%	-97.14%	49.02%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q